These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 27926505)
1. Antitumor effect of combination of the inhibitors of two new oncotargets: proton pumps and reverse transcriptase. Lugini L; Sciamanna I; Federici C; Iessi E; Spugnini EP; Fais S Oncotarget; 2017 Jan; 8(3):4147-4155. PubMed ID: 27926505 [TBL] [Abstract][Full Text] [Related]
2. Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma. Azzarito T; Venturi G; Cesolini A; Fais S Cancer Lett; 2015 Jan; 356(2 Pt B):697-703. PubMed ID: 25449440 [TBL] [Abstract][Full Text] [Related]
3. Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells. Federici C; Lugini L; Marino ML; Carta F; Iessi E; Azzarito T; Supuran CT; Fais S J Enzyme Inhib Med Chem; 2016; 31(sup1):119-125. PubMed ID: 27142956 [TBL] [Abstract][Full Text] [Related]
4. Non-nucleoside Reverse Transcriptase Inhibitors Inhibit Reverse Transcriptase through a Mutually Exclusive Interaction with Divalent Cation-dNTP Complexes. DeStefano JJ Biochemistry; 2019 Apr; 58(16):2176-2187. PubMed ID: 30900874 [TBL] [Abstract][Full Text] [Related]
5. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261 [TBL] [Abstract][Full Text] [Related]
6. Macrolide antibiotics enhance the antitumor effect of lansoprazole resulting in lysosomal membrane permeabilization‑associated cell death. Takeda A; Takano N; Kokuba H; Hino H; Moriya S; Abe A; Hiramoto M; Tsukahara K; Miyazawa K Int J Oncol; 2020 Dec; 57(6):1280-1292. PubMed ID: 33173988 [TBL] [Abstract][Full Text] [Related]
7. Proton pump inhibitors induce a caspase-independent antitumor effect against human multiple myeloma. Canitano A; Iessi E; Spugnini EP; Federici C; Fais S Cancer Lett; 2016 Jul; 376(2):278-83. PubMed ID: 27084522 [TBL] [Abstract][Full Text] [Related]
8. Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection. Wang J; Zhang G; Bambara RA; Li D; Liang H; Wu H; Smith HM; Lowe NR; Demeter LM; Dykes C J Virol; 2011 Oct; 85(20):10861-73. PubMed ID: 21835788 [TBL] [Abstract][Full Text] [Related]
9. Reverse transcriptase inhibitors promote the remodelling of nuclear architecture and induce autophagy in prostate cancer cells. Bellisai C; Sciamanna I; Rovella P; Giovannini D; Baranzini M; Pugliese GM; Zeya Ansari MS; Milite C; Sinibaldi-Vallebona P; Cirilli R; Sbardella G; Pichierri P; Trisciuoglio D; Lavia P; Serafino A; Spadafora C Cancer Lett; 2020 May; 478():133-145. PubMed ID: 32112906 [TBL] [Abstract][Full Text] [Related]
10. Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection. Haubrich RH; Riddler SA; Ribaudo H; Direnzo G; Klingman KL; Garren KW; Butcher DL; Rooney JF; Havlir DV; Mellors JW; AIDS; 2011 Nov; 25(18):2269-78. PubMed ID: 21941167 [TBL] [Abstract][Full Text] [Related]
11. Non-nucleoside reverse transcriptase inhibitor efavirenz increases monolayer permeability of human coronary artery endothelial cells. Jamaluddin MS; Lin PH; Yao Q; Chen C Atherosclerosis; 2010 Jan; 208(1):104-11. PubMed ID: 19674747 [TBL] [Abstract][Full Text] [Related]
12. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors. Hu Z; Kuritzkes DR J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199 [TBL] [Abstract][Full Text] [Related]
13. Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors. Yu M; Lee C; Wang M; Tannock IF Cancer Sci; 2015 Oct; 106(10):1438-47. PubMed ID: 26212113 [TBL] [Abstract][Full Text] [Related]
15. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Bélanger AS; Caron P; Harvey M; Zimmerman PA; Mehlotra RK; Guillemette C Drug Metab Dispos; 2009 Sep; 37(9):1793-6. PubMed ID: 19487252 [TBL] [Abstract][Full Text] [Related]
16. The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations. Wang J; Liang H; Bacheler L; Wu H; Deriziotis K; Demeter LM; Dykes C Virology; 2010 Jul; 402(2):228-37. PubMed ID: 20399480 [TBL] [Abstract][Full Text] [Related]
17. HIV nucleoside reverse transcriptase inhibitors efavirenz and tenofovir change the growth and differentiation of primary gingival epithelium. Mitchell D; Israr M; Alam S; Dinello D; Kishel J; Jia R; Meyers C HIV Med; 2014 Apr; 15(4):196-202. PubMed ID: 24580719 [TBL] [Abstract][Full Text] [Related]
18. The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study. Feng JY; Ly JK; Myrick F; Goodman D; White KL; Svarovskaia ES; Borroto-Esoda K; Miller MD Retrovirology; 2009 May; 6():44. PubMed ID: 19439089 [TBL] [Abstract][Full Text] [Related]
19. In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs. Hukezalie KR; Thumati NR; Côté HC; Wong JM PLoS One; 2012; 7(11):e47505. PubMed ID: 23166583 [TBL] [Abstract][Full Text] [Related]
20. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. De Milito A; Canese R; Marino ML; Borghi M; Iero M; Villa A; Venturi G; Lozupone F; Iessi E; Logozzi M; Della Mina P; Santinami M; Rodolfo M; Podo F; Rivoltini L; Fais S Int J Cancer; 2010 Jul; 127(1):207-19. PubMed ID: 19876915 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]